Comparative Pharmacology
Head-to-head clinical analysis: STATROL versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STATROL versus STERANE.
STATROL vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
10 mg orally once daily
100 mg orally every 12 hours
None Documented
None Documented
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Otic Antibiotic/Corticosteroid
Corticosteroid